Arterys IPO
Arterys developed cloud-based medical imaging software powered by AI for analyzing cardiac, liver, and lung conditions. The company was known for its FDA-cleared AI platform that helped radiologists quantify medical imaging data more efficiently. The acquisition reflected the strategic value of AI-powered medical imaging technology.
What We Know
Arterys was acquired by Tempus in 2021, preventing any potential IPO plans the company may have had. Tempus, an AI-enabled precision medicine company, integrated Arterys' medical imaging capabilities into its broader healthcare technology platform. Prior to the acquisition, Arterys had raised venture funding and built partnerships with major imaging equipment manufacturers. The acquisition by Tempus represented an exit for Arterys investors and employees, eliminating the possibility of an independent public offering.
Frequently Asked Questions
Has Arterys had an IPO?
No, Arterys did not have an IPO. The company was acquired by Tempus in 2021 before going public.
When is the Arterys IPO date?
There will be no Arterys IPO as the company was acquired by Tempus in 2021. Arterys no longer operates as an independent company.
How can I buy Arterys stock?
You cannot buy Arterys stock as the company was acquired by Tempus and no longer trades independently. Arterys' technology is now part of Tempus' platform.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts